MTOR and chronic myelogenous leukemia, BCR-ABL1 positive: The average drug sensitivity profiles between AML and CML cell lines were highly concordant (r = 0.78), with the exception of CML cells being more sensitive to Torin1 (mTOR inhibitor), cytarabine (nucleoside analog), and rotenone (complex I inhibitor) (Supplementary Fig. 1b).